CMPD Licensing, LLC (“CMPD”) holds numerous patents issued and pending in the United States.
Issued US Patents include, but are not necessarily limited to, the following:

  • US Patent 8,327,610
  • US Patent 8,464,498
  • US Patent 8,663,663
  • US Patent 8,895,036
  • US Patent 9,078,853
  • US Patent 9,186,319
  • US Patent 9,271,989
  • US Patent 9,468,599
  • US Patent 9,468,601
  • US Patent 9,592,241
  • US Patent 9,707,229
  • US Patent 9,717,748
  • US Patent 9,724,294
  • US Patent 9,724,315
  • US Patent 9,925,141
  • US Patent 9,962,391
  • US Patent 9,999,604
  • US Patent 10,064,949
  • US Patent 10,105,342
  • US Patent 10,105,381
  • US Patent 10,231,924
  • US Patent 10,434,115
  • US Patent 10,525,025
  • US Patent 10,610,503
  • US Patent 10,617,703
  • US Patent 10,660,962
  • US Patent 10,792,296
  • US Patent 10,813,897
  • US Patent 10,813,908
  • US Patent 10,898,455
  • US Patent 10,898.491
  • US Patent 10,973,804
  • US Patent 11,173,163
  • US Patent 11,207,336
  • US Patent 11,213,500
  • US Patent 11,213,501
  • US Patent 11,278,590
  • US Patent 11,311,564

This non-exhaustive list of patents does not address numerous patents-pending.

A licensee might be a pharmacy that: (a) either compounds or does not compound, (b) does or does not have a sales division, or (c) serves its local community only or instead a larger area through mailing prescriptions.

In addition to the obvious benefit of alleviating concerns about being engaged on potential infringement of CMPD’s patents, licensees may also receive additional services and benefits including, but not limited to, the following:

  • Access to two compounded formulas:
    • Diclofenac Sodium 1.5%, Lidocaine 2.5%, Prilocaine 2.5%
    • Gabapentin 3%, Diclofenac Sodium 1.5%, Lidocaine 2.5%, Prilocaine 2.5%
    • Both are cost-effective and often billable to a range of insurance plans including Medicare, Medicaid, federal and private plans.

  • Education regarding these two compounded formulas related to usage and documentation supporting the appropriateness of this approach
  • Education related to clinically appropriate approaches to promote nasal health (both compounded and commercially available medication options)
  • Assistance on controlling your cost-of-goods
  • Guidance on recommended “best practices” for compliance-driven pharmacy operations
  • Appropriate utilization of commercially available Lidocaine 2.5%-Prilocaine 2.5% Cream
  • Medication options related to ulcerative colitis
  • Generic-Effective-Rate education
  • Suggestions to mitigate fraud, waste, and abuse concerns of many industry payers and regulators, such as avoidance of: (a) various suspect creams and gels used for topical pain management, (b) certain high-priced generic tablets or capsules used for muscle relaxation or nasal/allergy symptoms, (c) various inappropriate non-soluble capsules, creams, and ointments often used in bath-irrigation or hydrotherapy delivery methodologies, and (d) manufacturer or wholesaler-sponsored “copay cards” that often run contrary to requirements for federal plan sponsors and/or PBM provider manual provisions
  • Suggestions for being viewed as a resource by prescribers, patients, payers and plan sponsors and
  • Potential access to additional addenda to the Licensing Agreement that allow ordering of limited-access items such as BASSA-GEL™ (

Interested in learning more about becoming a CMPD Licensee and-or having access to BASSA-GEL™? Please complete the form and you will receive more information about the opportunity.